<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04573244</url>
  </required_header>
  <id_info>
    <org_study_id>EMC 150-20</org_study_id>
    <nct_id>NCT04573244</nct_id>
  </id_info>
  <brief_title>Hemoglobin Easy Measurement With Optical Artificial Intelligence</brief_title>
  <acronym>HEMO-AI</acronym>
  <official_title>A Prospective Feasibility Study to Explore the Utility of Using a Smartphone Camera to Monitor Blood Hemoglobin Levels in Children and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MYOR Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MYOR Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Blood hemoglobin levels are an extremely important measure for a large swath of medical&#xD;
      procedures as they reflect the oxygen-carrying capacity of human blood. The gold standard&#xD;
      measure for blood hemoglobin levels involve a venous blood draw followed by a&#xD;
      laboratory-based complete blood count (CBC), a process which is both painful and time&#xD;
      consuming. To date, various methodologies have been tested to either expediate the process or&#xD;
      provide a non-invasive alternative. There remains a need to provide a quick,&#xD;
      pain-free/non-invasive and accurate modality to measure blood hemoglobin levels. The&#xD;
      objective of this study is to determine whether computer vision technologies can be applied&#xD;
      to fingernail images captured via a smartphone camera to quantify blood hemoglobin levels.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To determine whether computational learning methods can be applied to fingernail images captured via a smartphone camera to quantify blood hemoglobin levels.</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluated using the hemoglobin portion of a conventional complete blood count (CBC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine whether computational learning methods can be applied to fingernail images captured via a smartphone camera to screen for anemia as defined by the WHO</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluated using the hemoglobin portion of a conventional complete blood count (CBC). Anemia cutoff for children aged 6 months to 6 years = 11 g/dL and for children aged 6-14 years = 12 g/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine whether computational learning methods can be applied to fingernail images captured via a smartphone camera to quantify other elements of the CBC</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluated using the hemoglobin portion of a conventional complete blood count (CBC)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Hemoglobin; Deficiency</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Pediatric patients admitted to the Pediatric Emergency Department (PED) or Pediatric&#xD;
        Hematology Unit (PHU) who have undergone a CBC&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A patient aged 6 months to 18 years.&#xD;
&#xD;
          2. A patient who has undergone a venous blood draw for a CBC since being admitted to the&#xD;
             PED no more than 6 hours prior to study enrollment.&#xD;
&#xD;
          3. Parents or legal guardian provide informed written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient has subungual hematoma, nail bed lacerations or avulsion injuries on both&#xD;
             hands.&#xD;
&#xD;
          2. Patient has total leukonychia.&#xD;
&#xD;
          3. Patient has nail polish applied on fingernails.&#xD;
&#xD;
          4. Patient has nailbed darkening or discoloration due to medication.&#xD;
&#xD;
          5. Any other reason that, in the opinion of the investigator, prevents the subject from&#xD;
             participating in the study or compromise the patient safety.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilad Moshe Chayen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emek Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Brandwein</last_name>
    <phone>+972583325951</phone>
    <email>michael@myorcare.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emek Medical Center</name>
      <address>
        <city>Afula</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilad Moshe Chayen, MD</last_name>
      <email>gilad_ch@clalit.org.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>September 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

